The takeaway
ADMA Biologics Inc shows a pronounced seasonal pattern over 10 years of data — strongest in July (+11.0%) and softest in June (−7.2%).
Right now
In July, the stock has risen 70% of years, averaging +11.0%, about +8.9 pts better than the S&P 500.
The full picture
ADMA Biologics Inc's most dependable month has been July, higher in 7 of 10 years; June has been its least reliable, up just 10% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | ||||||||||||
| 2019 | ||||||||||||
| 2018 | ||||||||||||
| 2017 | ||||||||||||
| 2016 |
Month by month
The stock's clearest edge over the S&P 500 lands in March (+9.2 pts); it has trailed the market most in June (−7.4 pts).
“vs S&P” is ADMA Biologics Inc’s average for a month minus the S&P 500’s average for that same month — isolating ADMA Biologics Inc’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, July has closed higher 80% of the time versus 70% across the last 10 years — the pattern is strengthening.
Figures are the typical (median) July return and how often it rose — the last 5 years versus the last 10(the heatmap’s default window). This verdict stays anchored to that 10-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
Strip the year back and a single month does the heavy lifting: July, up in 7 of 10 Julys while the other eleven tend to blur together.
The headline flatters a touch — its +11.0% average sits well above the +5.9% a typical year delivers, the work of a few big Julys. That reliability comes with real swings, mind — even July ranges by 15.1% from year to year, so any single year can land far from the average. Crucially, the gain is the stock's own rather than a rising tide's: July has cleared the S&P 500 by +8.9 points above the index. Some of that is a strong month market-wide, mind — July rises for about 61% of stocks — so the tendency is real if not unique.
A few other months pull their weight: January, March, and April have also closed higher more often than not. The weaker half of the year is plainer: June has been the soft spot — the weakest of 5 months that average a loss (−7.2%), and the edge isn't year-round — the stock has trailed the S&P 500 in June, October, and December. Its roughest month on record was a −54.6% December in 2018 — a reminder of how hard even a seasonal name can fall.
If anything it has sharpened recently — the last five Julys run ahead of the earlier years.
The takeaway is less about when to buy than what to expect: July aside, the stock's months offer little reliable tilt. With returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (July), its worst (June), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2016 its best month (July, +11.0%) has run well ahead of its worst (June, −7.2%) — the heatmap above shows how steady that gap has been year to year.
July has been the strongest, averaging +11.0% and closing higher in 7 of 10 years since 2016.
It's the weakest, averaging −7.2% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade